Subscribe To
Iovance biotherapeutics to present clinical and pre-clinical data for tumor infiltrating lymphocyte (til) therapies at society for tumor immunotherapy of cancer's (sitc) 38th annual meeting
SAN CARLOS, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, dev...
October 31, 2023, 9:05 am
Iovance biotherapeutics to present clinical and pre-clinical data for tumor infiltrating lymphocyte (til) therapies at society for tumor immunotherapy of cancer's (sitc) 38th annual meeting
SAN CARLOS, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, de...
September 27, 2023, 4:01 pm
Iovance biotherapeutics to present at 2023 wells fargo healthcare conference
SAN CARLOS, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, d...
September 7, 2023, 11:31 am
Iovance biotherapeutics to present at 2023 wells fargo healthcare conference
SAN CARLOS, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, de...
September 7, 2023, 7:31 am
Iovance biotherapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)
SAN CARLOS, Calif., July 21, 2023 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, de...
July 21, 2023, 9:34 pm
Iovance biotherapeutics to host virtual roundtable with key opinion leaders to discuss melanoma treatment landscape
Investor Conference Call and Webcast on June 26 at 5:00 p.m. ET SAN CARLOS, Calif., June 20, 2023 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (...
June 20, 2023, 11:01 am
Iovance: capturing a lucrative market
Iovance Biotherapeutics, Inc. is poised to complete its rolling Biologic License Application for advanced melanoma this quarter. The recent Proleukin ...
February 1, 2023, 6:33 pm